Immunotherapy of cancer: are we already there?
Year: 2025
Type: article
Abstract: Recent status in cell-based cancer therapy, humoral-based cancer therapy and cancer vaccines will be discussed in short; This will be followed by presentation of data in chimeric antigen receptor (CAR)-therapy employing targeting moieties based on modified ERBB receptors’ ligands. The activity and efficacy of modified EGF-like domains derived from NRG1 (ligand to ErbB3 (HER3) receptor) and betacellulin (ligand to ErbB1 (EGFR) receptor) ligands as targeting moiety in CAR therapy will be presented.
Author: Angel Porgador
Institution: Ben-Gurion University of the Negev
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4408996008